

FOR IMMEDIATE RELEASE

CONTACTS:

Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223

Robert Liptak, Clarus Ventures, Tel.: 617-694-2222

Benjamin Carmichael, Russo Partners, Tel.: 212-845-4242

DR JEFFREY LEIDEN PROMOTED TO MANAGING DIRECTOR OF CLARUS VENTURES

Cambridge MA, September 10, 2007. Leading life sciences venture capital firm Clarus Ventures announced today that Dr. Jeff Leiden, former president and COO of Abbott's Pharmaceuticals business, has been promoted to managing director.

Dr. Leiden joined Clarus Ventures in November 2006 as partner from Abbott Pharmaceuticals where he managed the Company's global pharmaceuticals business. Since joining Clarus, Dr. Leiden has been involved in the sourcing, evaluating and funding of portfolio companies, including Variation Biotechnologies where he also serves as Chairman of the Board of Directors. He is also a non executive director of Shire.

"Jeff is a valued team member at Clarus. He has the unusual combination of a deep medical background, business acumen and leadership ability. This promotion recognizes Jeff's contributions to Clarus and our portfolio companies, and our expectations of his future contributions to the Firm," said Dr. Nick Galakatos, a managing director at Clarus.

"Clarus is a unique and exceptional environment for investing in innovative life sciences companies. I'm honored to be a member of this outstanding team of investment professionals and scientists and I look forward to contributing to the continued success of the firm as a Managing Director," said Dr. Leiden.

Dr. Leiden trained at the University of Chicago where he received his MD and PhD degrees. He then became associate professor of medicine at the University of Michigan, chief of cardiology at the University of Chicago, and professor of medicine at Harvard Medical School. During his 14 year career in academia, Dr. Leiden published more than 130 peer reviewed papers and helped start three biotechnology companies, two of which are now publicly traded (CV Therapeutics and Vical), and Cardiogene, which was sold to Boston Scientific. Among his many distinctions, Dr. Leiden is an elected member of the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences.

About Clarus Ventures

Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Deep relationships with industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The Firm manages \$500 million through its inaugural fund, Clarus Lifesciences I, L.P. and has offices in Cambridge, MA and San Francisco, CA.

For additional information on Clarus Ventures please visit www.clarusventures.com.